Meeting
2018 ASCO Annual Meeting
Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
Authors
Andrea Wang-Gillam
Washington University School of Medicine in St. Louis, St. Louis, MO
Andrea Wang-Gillam , A. Craig Lockhart , Benjamin R. Tan Jr., Rama Suresh , Kian-Huat Lim , Lee Ratner , David G. DeNardo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Clinical Trial Registration Number
02546531
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2561)
DOI
10.1200/JCO.2018.36.15_suppl.2561
Abstract #
2561
Poster Bd #
387
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
First Author: Andrea Wang-Gillam
Poster
2017 Gastrointestinal Cancers Symposium
Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer.
First Author: Andrea Wang-Gillam
Poster
2023 ASCO Annual Meeting
Preliminary translational immune and stromal correlates in a randomized phase II trial of pembrolizumab with or without defactinib for resectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Anser Ali Abbas
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang